Tesamorelin vs sermorelin: which growth hormone peptide is right for you
Tesamorelin and sermorelin are both growth hormone-releasing hormone (GHRH) analogs. Both stimulate the pituitary to release the body's own growth hormone in pulses. They differ in molecule size, half-life, FDA history, evidence base, and the patient profiles they fit best. This guide walks the comparison honestly and helps the patient choose.
6 min read · Updated May 6, 2026
Medically reviewed by Dr. Jonathan Snipes, MD (NPI 1821250077). Last reviewed May 6, 2026.
The short answer
Sermorelin is a 29-amino acid GHRH analog with a short half-life. It produces a brief, natural-feeling pulse of growth hormone and was originally FDA-approved as Geref in 1997. Tesamorelin is a 44-amino acid GHRH analog with stabilizing modifications that extend half-life. It is FDA-approved as Egrifta (2010) for HIV-associated lipodystrophy and has the strongest evidence base for visceral adiposity reduction. Both are legal under Section 503A patient-specific compounding; both ship pre-reconstituted from Optimal Balance Pharmacy at PeptideRx.
Side-by-side comparison
| Sermorelin | Tesamorelin | |
|---|---|---|
| Molecule size | 29 amino acids | 44 amino acids |
| Mechanism | GHRH analog (short) | GHRH analog (extended) |
| FDA approval | Geref (1997, discontinued) | Egrifta (2010, active) |
| Approved indication | Pediatric GHD diagnostic | HIV-associated lipodystrophy |
| Half-life | ~10-20 minutes | ~26-38 minutes (longer effect) |
| Visceral fat data | Limited dedicated data | Strongest evidence (Egrifta trials) |
| Best for | Gentle GH support, age-management | Visceral adiposity, lipodystrophy |
| PeptideRx pairing | Sermorelin or Sermorelin/Ipamorelin | Tesamorelin or Tesamorelin/Ipamorelin |
| Starter price | $80 / 15 mg | Per provider |
How they both work
Both peptides bind growth hormone-releasing hormone (GHRH) receptors on the anterior pituitary. The pituitary then releases its own stored growth hormone in a pulse. The body’s natural negative feedback (somatostatin tone) remains intact, which is why GHRH analogs are considered safer than supraphysiologic synthetic HGH for long-term use. Both peptides preserve the natural pulsatile pattern of GH release that healthy pituitary function produces.
The difference is how long the analog stays at the receptor. Sermorelin has a half-life of 10 to 20 minutes; the GH pulse arrives quickly and resolves quickly. Tesamorelin has structural modifications that extend the half-life to 26 to 38 minutes, which produces a longer and stronger GH pulse per dose.
Evidence base
Sermorelin was FDA-approved as Geref in 1997 for diagnostic use and pediatric growth hormone deficiency. The branded product was later discontinued for commercial reasons, but the molecule remains FDA-listed and eligible for 503A compounding. Adult age-management use of sermorelin is off-label but supported by 30+ years of clinical use. Improvements in body composition, sleep depth, and skin elasticity over a 3 to 6 month protocol are consistently reported.
Tesamorelin was FDA-approved as Egrifta in 2010 for HIV-associated lipodystrophy. The Egrifta pivotal trials (Phase III, two parallel randomized controlled trials) showed significant reduction in visceral adipose tissue (~15 to 18 percent mean reduction over 26 weeks) with an acceptable safety profile. Off-label use in non-HIV patients for visceral adiposity targeting is supported by the same mechanistic and safety data, though the formal indication is limited.
When each makes sense
Choose sermorelin if you want gentle GH support, your goal is general anti-aging or sleep quality, you respond well to the natural pulsatile pattern of release, or you prefer the shorter-acting molecule. Sermorelin is also the more affordable option at PeptideRx ($80 for the 15 mg starter vial). Many providers pair it with ipamorelin for additive ghrelin-receptor effect.
Choose tesamorelin if visceral adiposity reduction is the specific goal (the Egrifta evidence base is uniquely strong here), you want a longer-acting GHRH effect, or you have HIV lipodystrophy and want the FDA-approved indication. Tesamorelin also pairs with ipamorelin for a stronger combined GH pulse; see Tesamorelin/Ipamorelin.
Bottom line
Sermorelin is the gentler short-acting GHRH analog with 30+ years of clinical use and an off-label safety record. Tesamorelin is FDA-approved as Egrifta with the strongest visceral-adiposity evidence in any GH peptide. Both are legitimate clinical tools for different patient profiles. Both are legal under Section 503A patient-specific compounding. Both ship pre-reconstituted from Optimal Balance Pharmacy.
Continue reading